| Identification | Back Directory | [Name]
3-[2-[[3-[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-2-propyn-1-yl]oxy]ethoxy]propanoic acid (ACI) | [CAS]
2797619-65-7 | [Synonyms]
3-[2-[[3-[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-2-propyn-1-yl]oxy]ethoxy]propanoic acid (ACI) | [Molecular Formula]
C21H20N2O8 | [MOL File]
2797619-65-7.mol | [Molecular Weight]
428.39 |
| Chemical Properties | Back Directory | [Boiling point ]
723.0±60.0 °C(predicted) | [density ]
1.48±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
4.27±0.10(predicted) | [color ]
Yellow to brown |
| Hazard Information | Back Directory | [Uses]
Thalidomide-Propargyne-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. Thalidomide-Propargyne-PEG2-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [IC 50]
Cereblon | [References]
[1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-989. DOI:10.1016/j.devcel.2020.07.018 |
|
|